Business Wire

Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s

Share

Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that following a re-examination procedure the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Parkinson’s is a chronic, progressive neurodegenerative condition that affects small regions in the brain that control movement, balance and posture.1 It is the fastest growing neurodegenerative disorder in the world.2

“We are disappointed by the CHMP opinion. We will take time to assess our plans for istradefylline in EMEA,” said Tomohiro Sudo, Executive Officer, Head of Global Product Strategy Department at Kyowa Kirin. “We appreciate the collaboration we have had with all stakeholders and applaud the Parkinson’s community for their commitment to supporting people living with this chronic, debilitating condition.”

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. The company is committed to bringing our innovative therapies to patients.

About istradefylline

Istradefylline was developed as a novel, first-in-class non-dopaminergic, adenosine A2A receptor antagonist that reduces ‘OFF’ time in people living with Parkinson’s through selective targeting of adenosine A2A receptors in the basal ganglia. Whilst dopaminergic treatment targets the dopamine receptors in the direct and indirect pathways to facilitate movement, istradefylline, as an add-on to L-Dopa, reduces the activity of the indirect pathway which suppresses movement.3,4 Consequently, it helps restore the balance within the basal ganglia.1,2

About Parkinson’s and ‘OFF’ episodes

There are an estimated 10 million people in the world currently living with Parkinson’s.5 Although it is classically characterised by motor symptoms (symptoms involving movement), people living with the condition also experience a large range of non-motor symptoms, which add to the complexity of living with the condition.5 Although Parkinson’s is not life threatening there is currently no cure.1 Over time symptoms progress and can be unpredictable, imposing a significant impact on daily life.1 This impact can extend to caregivers, friends and family, whose own wellbeing and quality of life can deteriorate as a result.6

‘OFF’ episodes is used to describe the return of Parkinson’s symptoms, also known as ‘OFF’ symptoms, and can be triggered by a variety of phenomena, including:7

  • Delayed onset of response to medication
  • Reduced duration of benefit from a medication
  • Reduced or no efficacy of a dose of medication

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.

Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.

Kyowa Kirin International

http://www.international.kyowa-kirin.com /

Galabank Business Park
Galashiels, TD1 1QH
United Kingdom

References


1. European Parkinsons Disease Association. About Parkinson’s, https://www.epda.eu.com/about-parkinsons/what-is-parkinsons/ [Last accessed Novemeber 2021].

2. Dorsey ER, Sherer T, Okun MS, et al. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis 2018; 8: S3-s8. 2018/12/26. DOI: 10.3233/jpd-181474.

3. Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 963-972. 2013/07/03. DOI: 10.1007/s00210-013-0897-5.

4. LeWitt PA, Aradi SD, Hauser RA, et al. The challenge of developing adenosine A(2A) antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord 2020; 80 Suppl 1: S54-s63. 2020/12/23. DOI: 10.1016/j.parkreldis.2020.10.027.

5. Ball N, Teo W-P, Chandra S, et al. Parkinson's Disease and the Environment. Frontiers in Neurology 2019; 10. Mini Review. DOI: 10.3389/fneur.2019.00218.

6. Armstrong MJ, Rastgardani T, Gagliardi AR, et al. The impact of off periods on persons with Parkinson’s and care partners: a qualitative study. Neurol Clin Pract 2020;10.1212/CPJ.0000000000000921.

7. Freitas ME, Hess CW and Fox SH. Motor Complications of Dopaminergic Medications in Parkinson's Disease. Semin Neurol 2017; 37: 147-157. 2017/05/17. DOI: 10.1055/s-0037-1602423.

KKI/INT/IST/0142
Date of preparation: November 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for Kyowa Kirin International:
Media
Sarah Evans
Email: Sarah.Evans@kyowakirin.com

Contacts for Kyowa Kirin Co., Ltd.:
Media
Hiroki Nakamura
Email: media@kyowakirin.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Honor to Knight! DRAG S/X PnP-X Kit Is Launched2.12.2021 10:35:00 CET | Press release

In November, VOOPOO announced the overseas launch of the DRAG S/X PnP-X KIT. The product carries out comprehensive technical upgrading on the basis of DRAG S/X, endows the core concept of "Chivalry" in product design, and pays tribute to the glory and virtue of knights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005381/en/ (Photo: Business Wire) Originated from the spirit of martial arts of German in the Middle Ages, the spirit of chivalry was then embodied in soldiers of the European battlefield in the 11th century, and guards of emperors and warriors of Christ. Nowadays, chivalry is culturally continued and nobly expressed as gentleman demeanor. Despite passage of time, the only constant is the faith that knight loyally holds and eight virtues of knights flowing in their blood. After learning about this legendary medieval history and digging out the core of chivalry, VOOPOO design and R&D personnel were deeply to

Zilliant Announces Significant Growth in Europe2.12.2021 09:30:00 CET | Press release

Zilliant, the industry leader in intelligent B2B price optimization, price management and sales guidance software, today announced significant growth in Europe, marked by compound annual revenue growth of 55% from 2018-2021 as well as significant growth of new customers. “B2B company leaders are increasingly seeking alternatives to the traditional means of managing prices and enabling sales teams,” said Zilliant President and Chief Executive Officer Greg Peters. “Tying strategy to effective execution can be even more difficult for companies in Europe, particularly in global, multi-country businesses. Our growth in the region can be attributed to the increased breadth of our product portfolio, addressing the full spectrum of pricing challenges in B2B, and our passion for powering intelligent commerce for our customers.” Zilliant maintains offices in Paris, London, Milan, Italy, and Walldorf, Germany. In recent years, a wide variety of B2B companies in Europe with worldwide operations ha

Hopp Secures $2.8 Million Funding From Brunnur Ventures to Build a Global Sustainable Micromobility Sharing Franchise2.12.2021 09:27:00 CET | Press release

Hopp (www.hopp.bike),the sustainable electric scooter rental company, is pleased to announce an investment by Brunnur Ventures of $2.8 million into the company to drive international growth of its worldwide franchise strategy. Hopp is the sustainable transportation solution for the world’s modern city enabling riders to travel without leaving a carbon footprint. Hopp's primary mission is to leave behind a cleaner planet, one ride at a time, with all parts of the business carbon negative. Hopp is uniquely focused on smaller cities, local travel and smaller fleets – an almost untouched market as more than 95% of cities in Europe with less than 500,000 inhabitants are currently unserved. “Our goal is to influence the electric scooter market in the same way as McDonald’s for the hamburger,” commented CEO Eythór Steinarsson. “We want to bring this technology to smaller cities where there is a big opportunity and to get locals to work with us. We want to bring the sharing economy to the way

Bitcoin Capital Expands its Crypto Asset Offering2.12.2021 09:11:00 CET | Press release

Bitcoin Capital announced today that it has again listed two world firsts on the SIX Swiss Exchange. With 1 FiCAS Active Bitcoin ETP and 1 FiCAS Active Ethereum ETP, the company has launched two products actively managed by the highly experienced crypto asset manager FICAS AG. With active management, the products aim to counter negative price fluctuations and therefore outperform the two largest cryptocurrencies by capitalization. With the listing, institutional, professional, and private investors in Switzerland, Liechtenstein, and the European Union (excluding Hungary) can easily invest in the new products via their bank or broker, just as they do with other listed financial investments such as equities or bonds. "Our purpose is to grant investors safe and easy access to digital assets and are convinced that crypto assets will soon be part of the diversification strategy of many investment portfolios. The two new products with the most relevant cryptocurrencies as underlying may, thr

Ricardo Announces Approved Science-based Targets as We Advance Towards Net Zero2.12.2021 09:00:00 CET | Press release

Ricardo, a world-class environmental, engineering and strategic-consulting company, is pleased to announce that our proposed greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi) and that they are in line with the goals set forth in the 2015 Paris Agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005044/en/ Ricardo is pleased to announce that proposed greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (Graphic: Business Wire) The Science Based Targets initiative (SBTi) is a collaboration between the CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). We now join a growing group of global businesses that have received approval of their targets, ensuring that greenhouse gas emissions from Ricardo’s operations (scopes 1 and 2)1 are consistent with t

Eurofins Technologies Launches Wastewater Diagnostic Kit for SARS-CoV-2 Testing Including Identification of Omicron Variant2.12.2021 09:00:00 CET | Press release

Eurofins Technologies announces the launch of the VIRSeek SARS-CoV-2 Mplex I and Mplex II Wastewater real-time RT-PCR kits to provide an efficient solution for SARS-CoV-2 detection in wastewater, including the Omicron variant of concern. Wastewater-based epidemiology has become an important approach in order to comprehensively monitor the profile of SARS-CoV-2 infections in highly populated areas. Methods to detect SARS-CoV-2 viral RNA in untreated wastewater have advanced over the last number of months. Data has shown that concentrations of viral RNA correlate with trends in reported COVID-19 cases, demonstrating the importance of wastewater testing as a public health tool. The European Commission has recommended1 the implementation of effective systems for the surveillance of SARS-CoV-2 in wastewater. The VIRSeek SARS-CoV-2 Mplex I and Mplex II Wastewater real-time RT-PCR kits delivers an effective solution for SARS-CoV-2 detection in wastewater. The VIRSeek SARS-CoV-2 Wastewater kit

BMC TV delivers Paralympic coverage to UK with ADVA FSP 1502.12.2021 09:00:00 CET | Press release

ADVA (FSE: ADV) today announced that BMC TV deployed its FSP 150 Carrier Ethernet technology to transport coverage of the Paralympic Games from Tokyo to London. The robust, low-power solution empowered BMC TV to cost-effectively provide highly reliable services, enabling hundreds of hours of live broadcasting on high-definition television and online streams. The close support of ADVA’s team, together with the ease of use of its FSP 150 device, helped to ensure the success of the project. Fiber optic solutions provider Fibre Technologies also played a key role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005059/en/ ADVA’s FSP 150 technology helped BMC TV bring coverage of the Tokyo Paralympics to an audience of over 20 million people. (Photo: Business Wire) “We’re proud to have helped bring high-quality coverage of the Paralympics to a UK audience of over 20 million. By harnessing ADVA’s edge Ethernet equipment, we w